Article
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
The Journal of infectious diseases - 15 Jun 2001
Eshleman S H, Krogstad P, Jackson J B, Wang Y G, Lee S, Wei L J, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P
Abstract excerpt
In Pediatric AIDS Clinical Trials Group 377, antiretroviral therapy-experienced children were randomized to 4 treatment arms that included different combinations of stavudine, lamivudine (3TC), nevirapine (Nvp), nelfinavir (Nfv), and ritonavir (Rtv). Previous treatment with zidovudine (Zdv), didanosine (ddI), or zalcitabine (ddC) was acceptable. Drug resistance mutations were assessed before study treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.